TELA Bio, Inc. 8-K

What Happened

• TELA Bio, Inc. (TELA) filed a Form 8-K (Item 3.01) on March 20, 2026 stating that on March 17, 2026 Nasdaq notified the company that the closing bid price for TELA common stock has been below the $1.00 minimum required for continued listing on The Nasdaq Global Market for the last 30 consecutive business days. Nasdaq’s deficiency letter does not have an immediate effect—TELA shares continue to trade under the symbol "TELA."

Key Details

• Nasdaq deficiency letter date: March 17, 2026; Form 8-K filed March 20, 2026.
• Regain compliance requirement: closing bid of $1.00 or more for at least 10 consecutive business days.
• Initial cure period: 180 calendar days, until September 14, 2026.
• If not cured, a potential second 180-day period may be available only if TELA transfers to The Nasdaq Capital Market and meets other initial listing standards (except the minimum bid price), and notifies Nasdaq of intent to cure.
• If Nasdaq concludes the deficiency cannot be cured or TELA fails to regain compliance after available periods, Nasdaq may initiate delisting; TELA could appeal to a Nasdaq Hearings Panel, but success is not assured.

Why It Matters

• A sustained bid price below $1.00 puts TELA at risk of delisting, which can reduce liquidity and make shares harder to trade for retail investors.
• The company has a defined window (through Sept 14, 2026) to restore compliance by raising its stock price or pursue the specified transfer and cure process; there is no guarantee this will succeed.
• Investors should monitor TELA’s stock price, any corporate actions the company announces to address the deficiency, and further filings about Nasdaq correspondence or appeals.